Luminex Looks to Target Mid- to Low-Volume MDx Labs with GenturaDx Platform | GenomeWeb

Luminex this week made a play for the low- to mid-volume molecular diagnostic testing market by when it announced that it is acquiring privately held molecular diagnostics developer GenturaDx for $50 million.

With the acquisition, Luminex will inherit GenturaDx's IDBox platform, a fully integrated and automated real-time PCR system that uses disposable testing cassettes — a "tried and true industry-standard approach," Luminex President and CEO Patrick Balthrop told PCR Insider.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.